Streetbeat News

NRSN

NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com

Industry

Biotechnology

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Open

1.25

Mkt cap

23M

Volume

121K

High

1.26

P/E Ratio

-1.82

52-wk high

2.33

Low

1.14

Div yield

N/A

52-wk low

0.47

NeuroSense Therapeutics has been granted a U.S. patent for its novel PrimeC formulation, extending its intellectual property protection through 2042. This strengthens the company's IP position by adding four additional years to its coverage.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:06 pm

NeuroSense Therapeutics Ltd. has received a notification from Nasdaq for not meeting the minimum bid price requirement, as its stock has been below $1.00 for 30 consecutive trading days.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:31 pm

NeuroSense Therapeutics is in discussions that could lead to significant financial benefits, including upfront, milestone, and royalty payments. These discussions are based on non-binding terms.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:02 am

NeuroSense Therapeutics is in advanced discussions with several major pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for ALS treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:02 am

NeuroSense Therapeutics is in advanced talks with several large pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug, PrimeC, for ALS. The discussions could lead to significant financial benefits for NeuroSense, though no definitive agreement has been reached yet.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 11:00 am

NeuroSense Therapeutics has entered into a Capital On Demand Sales Agreement with JonesTrading Institutional Services, allowing the company to offer and sell ordinary shares for up to $2.5 million in gross sale proceeds, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 8:14 pm

NeuroSense Therapeutics has announced a $600K private placement agreement, selling 800K ordinary shares and 800K warrants at $0.75 per share, which is 10% above the August 6 closing price.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 6:00 pm

NeuroSense Therapeutics announced positive 12-month biomarker data from its Phase 2b clinical trial for PrimeC, showing significant improvements in ALS-related biological markers, safety, and efficacy. The trial demonstrated reduced functional and respiratory deterioration, regulation of iron levels, and improved survival rates.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 1:22 pm

NeuroSense shares are trading higher following positive results from a 12-month analysis of its PARADIGM Phase 2b study. The study showed that PrimeC slowed ALS disease progression by 36% compared to the placebo.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:04 pm

NeuroSense has reported results from a 12-month analysis of its PARADIGM Phase 2b study evaluating PrimeC in ALS patients. The study showed that disease progression was slowed by 36% compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.